Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are a novel ablation company committed to health innovation using our patented Nano-pulse Stimulation (“NPS”) technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to nonthermally clear or kill targeted cells. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation (“nsPFA”) technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Business segments
Q2 2022 · $265.0KThe company’s own SEC segment disclosure.
- System Products$209.0K79%
- Cycle Units Products$56.0K21%
Pulse Biosciences, Inc. (PLSE) reported revenue of $401K in Q1 2026 (quarter ended March 31, 2026). That came with a gross margin of 7.7% and net loss of $19M. For the full year FY2025, revenue was $350K and net income −$73M. Its largest product in 2022-Q2 was System Products at $209K, 79% of the disclosed total, just ahead of Cycle Units Products at 21%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Medical Instruments & Supplies
Ranks #15 of 27 by Smart Score